Capricor Therapeutics Stock Performance
| CAPR Stock | USD 7.96 0.18 2.31% |
The firm shows a Beta (market volatility) of 3.91, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Capricor Therapeutics will likely underperform. Capricor Therapeutics right now shows a risk of 9.04%. Please confirm Capricor Therapeutics semi variance, and the relationship between the treynor ratio and daily balance of power , to decide if Capricor Therapeutics will be following its price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Capricor Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Capricor Therapeutics is not utilizing all of its potentials. The recent stock price agitation, may contribute to short-term losses for the retail investors. ...more
Actual Historical Performance (%)
One Day Return 2.31 | Five Day Return 0.63 | Year To Date Return (46.79) | Ten Year Return (80.25) | All Time Return (98.23) |
Last Split Factor 1:10 | Dividend Date 2019-06-05 | Last Split Date 2019-06-05 |
1 | SHAREHOLDER ALERT Levi Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Capricor Therapeutics, Inc. Securi... | 07/17/2025 |
2 | Capricor Therapeutics, Inc.s 15 percent loss last week hit both individual investors who own 47 percent as well as institutions | 07/22/2025 |
3 | Class Action Filed Against Capricor Therapeutics, Inc. - September 15, 2025 Deadline to Join Contact Levi Korsinsky | 07/28/2025 |
4 | Investors in Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights CAPR | 08/04/2025 |
5 | Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13 | 08/06/2025 |
6 | Quanterix Corporation Reports Q2 Loss, Misses Revenue Estimates | 08/07/2025 |
7 | Capricor stock rises on FDA meeting for rejected drug | 08/08/2025 |
8 | Capricor Q2 Earnings Snapshot | 08/11/2025 |
9 | Capricor Therapeutics, Inc. Q2 2025 Earnings Preview | 08/12/2025 |
10 | Levi Korsinsky Notifies Shareholders of Capricor Therapeutics, Inc. of a Class Action Lawsuit and an Upcoming Deadline | 08/14/2025 |
| Begin Period Cash Flow | 14.7 M | |
| Total Cashflows From Investing Activities | -116.2 M |
Capricor Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,037 in Capricor Therapeutics on May 18, 2025 and sell it today you would lose (241.00) from holding Capricor Therapeutics or give up 23.24% of portfolio value over 90 days. Capricor Therapeutics is currently generating 0.0139% in daily expected returns and assumes 9.0357% risk (volatility on return distribution) over the 90 days horizon. In different words, 80% of stocks are less volatile than Capricor, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Capricor Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Capricor Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Capricor Therapeutics, and traders can use it to determine the average amount a Capricor Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0015
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CAPR |
Estimated Market Risk
| 9.04 actual daily | 81 81% of assets are less volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Capricor Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Capricor Therapeutics by adding Capricor Therapeutics to a well-diversified portfolio.
Capricor Therapeutics Fundamentals Growth
Capricor Stock prices reflect investors' perceptions of the future prospects and financial health of Capricor Therapeutics, and Capricor Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Capricor Stock performance.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.35 | ||||
| Operating Margin | (5.48) % | ||||
| Current Valuation | 233.92 M | ||||
| Shares Outstanding | 45.72 M | ||||
| Price To Earning | 42.39 X | ||||
| Price To Book | 3.39 X | ||||
| Price To Sales | 26.56 X | ||||
| Revenue | 22.27 M | ||||
| Gross Profit | (53.93 M) | ||||
| EBITDA | (41.14 M) | ||||
| Net Income | (40.47 M) | ||||
| Cash And Equivalents | 51.42 M | ||||
| Cash Per Share | 2.11 X | ||||
| Total Debt | 1.45 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 2.69 X | ||||
| Book Value Per Share | 2.79 X | ||||
| Cash Flow From Operations | (40 M) | ||||
| Earnings Per Share | (1.59) X | ||||
| Market Capitalization | 355.68 M | ||||
| Total Asset | 170.48 M | ||||
| Retained Earnings | (199.83 M) | ||||
| Working Capital | 142.36 M | ||||
| Current Asset | 22.4 M | ||||
| Current Liabilities | 6.67 M | ||||
About Capricor Therapeutics Performance
Assessing Capricor Therapeutics' fundamental ratios provides investors with valuable insights into Capricor Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Capricor Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.25) | |
| Return On Capital Employed | (0.28) | (0.30) | |
| Return On Assets | (0.24) | (0.25) | |
| Return On Equity | (0.28) | (0.26) |
Things to note about Capricor Therapeutics performance evaluation
Checking the ongoing alerts about Capricor Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Capricor Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Capricor Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 22.27 M. Net Loss for the year was (40.47 M) with loss before overhead, payroll, taxes, and interest of (53.93 M). | |
| Capricor Therapeutics currently holds about 51.42 M in cash with (40 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.11. | |
| Capricor Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 17.0% of the company shares are held by company insiders | |
| Latest headline from globenewswire.com: Levi Korsinsky Notifies Shareholders of Capricor Therapeutics, Inc. of a Class Action Lawsuit and an Upcoming Deadline |
- Analyzing Capricor Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Capricor Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Capricor Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Capricor Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Capricor Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Capricor Therapeutics' stock. These opinions can provide insight into Capricor Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.